MX358137B - Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso. - Google Patents
Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso.Info
- Publication number
- MX358137B MX358137B MX2014000093A MX2014000093A MX358137B MX 358137 B MX358137 B MX 358137B MX 2014000093 A MX2014000093 A MX 2014000093A MX 2014000093 A MX2014000093 A MX 2014000093A MX 358137 B MX358137 B MX 358137B
- Authority
- MX
- Mexico
- Prior art keywords
- arginine
- methods
- compositions
- exempts
- fusion polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161504110P | 2011-07-01 | 2011-07-01 | |
| PCT/US2012/044988 WO2013006454A1 (en) | 2011-07-01 | 2012-06-29 | Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014000093A MX2014000093A (es) | 2014-11-12 |
| MX358137B true MX358137B (es) | 2018-08-06 |
Family
ID=46579322
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009524A MX421100B (es) | 2011-07-01 | 2012-06-29 | Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso |
| MX2014000093A MX358137B (es) | 2011-07-01 | 2012-06-29 | Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009524A MX421100B (es) | 2011-07-01 | 2012-06-29 | Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10995130B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2726090B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6463968B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102061355B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN113244374A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2012279205B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013033671B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2840711C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2726090T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA026226B1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX421100B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013006454A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201400490B (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007015476A (es) | 2005-06-14 | 2008-02-25 | Amgen Inc | Formulaciones de proteina autoamortiguadoras. |
| EP3569243A1 (en) | 2011-06-28 | 2019-11-20 | Inhibrx, LP | Serpin fusion polypeptides and methods of use thereof |
| EA026226B1 (ru) | 2011-07-01 | 2017-03-31 | Байоджен Айдек Ма Инк. | Не содержащие аргинина композиции слитого fc-полипептида и способы их применения |
| US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| CN104010658A (zh) | 2011-10-18 | 2014-08-27 | 科荣生生物科学公司 | 使用葡甲胺稳定的依那西普制剂 |
| EP2869817A4 (en) * | 2012-07-09 | 2016-04-06 | Coherus Biosciences Inc | STABLE AQUEOUS FORMULATIONS OF ETANERCEPT |
| CN104768576A (zh) | 2012-09-07 | 2015-07-08 | 科荣生生物科学公司 | 稳定的阿达木单抗水性制剂 |
| AU2013315750B9 (en) | 2012-09-11 | 2018-11-15 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
| EP2926834A4 (en) * | 2012-11-27 | 2016-04-20 | Alteogen Inc | COMPOSITION FOR STABILIZING A FUSION PROTEIN IN WHICH A PROTEIN AND A DOMAIN FC ARE MERGED |
| RU2663727C2 (ru) * | 2013-05-02 | 2018-08-08 | Мабксьенсе С.А. | Альтернативные составы для химерных полипептидов tnfr:fc |
| WO2015056613A1 (ja) * | 2013-10-15 | 2015-04-23 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 安定化されたポリペプチド水性製剤 |
| ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
| EP2946766B1 (en) | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP2946765B1 (en) | 2014-05-23 | 2016-08-31 | Ares Trading S.A. | Liquid pharmaceutical composition |
| US9821059B2 (en) * | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
| EP3236990B1 (en) | 2014-12-22 | 2020-09-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| KR20240132521A (ko) * | 2015-03-13 | 2024-09-03 | 삼성바이오에피스 주식회사 | 항-tnf-알파 폴리펩티드 조성물 및 그 용도 |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
| CA3040899A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
| WO2018080196A2 (ko) * | 2016-10-28 | 2018-05-03 | (주)셀트리온 | 안정한 약제학적 제제 |
| US11253569B2 (en) | 2018-05-03 | 2022-02-22 | Seattle Children's Hospital | Methods of treating Kawasaki Disease |
| CN111228225B (zh) * | 2018-11-28 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂 |
| GB201901547D0 (en) * | 2019-02-05 | 2019-03-27 | Arecor Ltd | Stabilized Fc Fusion protein solutions |
| CN118510549A (zh) * | 2021-09-22 | 2024-08-16 | 圣诺制药公司 | 具有减小的纳米颗粒尺寸和改善的多分散性指数的纳米颗粒药物组合物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| AU4363200A (en) | 1999-04-19 | 2000-11-02 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical desorders |
| US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US6818613B2 (en) | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
| EP3192528A1 (en) * | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
| EP3210624A1 (en) * | 2002-02-27 | 2017-08-30 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| ES2311094T3 (es) | 2002-02-27 | 2009-02-01 | Immunex Corporation | Composicion estabilizada de tnfr-fc que comprende arginina. |
| KR100471843B1 (ko) | 2002-06-11 | 2005-03-08 | 현대자동차주식회사 | 자동차의 아웃사이드 웨더스트립 장착구조 |
| HUE051878T2 (hu) | 2003-02-10 | 2021-03-29 | Biogen Ma Inc | Immunglobulin készítmény és annak elõállítási módszere |
| ATE394123T1 (de) | 2003-02-28 | 2008-05-15 | Ares Trading Sa | Flüssige formulierungen des tumornekrosefraktor- bindungsproteins tbp-1 |
| WO2005012353A1 (en) | 2003-08-01 | 2005-02-10 | Amgen Inc. | Crystalline tumor necrosis factor receptor 2 polypeptides |
| TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| MX2007015476A (es) | 2005-06-14 | 2008-02-25 | Amgen Inc | Formulaciones de proteina autoamortiguadoras. |
| US20110046059A1 (en) * | 2005-09-06 | 2011-02-24 | Zelos Therapeutics, Inc. | Pharmaceutically acceptable formulations/compositions for peptidyl drugs |
| MX2008013535A (es) * | 2006-04-21 | 2008-10-29 | Amgen Inc | Agentes amortiguadores para formulaciones biofarmaceuticas. |
| TW200833357A (en) | 2006-10-20 | 2008-08-16 | Amgen Inc | Stable polypeptide formulations |
| JP2010523695A (ja) * | 2007-04-11 | 2010-07-15 | アルコン リサーチ， リミテッド | アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのＴＮＦαのインヒビターおよび抗ヒスタミン薬の使用 |
| TW200938221A (en) | 2007-11-30 | 2009-09-16 | Abbott Lab | Protein formulations and methods of making same |
| EP2598167B1 (en) * | 2010-07-30 | 2015-04-01 | Arecor Limited | Stabilized aqueous antibody compositions |
| EA026226B1 (ru) | 2011-07-01 | 2017-03-31 | Байоджен Айдек Ма Инк. | Не содержащие аргинина композиции слитого fc-полипептида и способы их применения |
-
2012
- 2012-06-29 EA EA201490195A patent/EA026226B1/ru unknown
- 2012-06-29 DK DK12738670.4T patent/DK2726090T3/da active
- 2012-06-29 CN CN202110408576.1A patent/CN113244374A/zh active Pending
- 2012-06-29 JP JP2014519158A patent/JP6463968B2/ja active Active
- 2012-06-29 CN CN201280032584.XA patent/CN103930124B/zh active Active
- 2012-06-29 US US14/128,846 patent/US10995130B2/en active Active
- 2012-06-29 CA CA2840711A patent/CA2840711C/en active Active
- 2012-06-29 EP EP12738670.4A patent/EP2726090B1/en active Active
- 2012-06-29 AU AU2012279205A patent/AU2012279205B2/en active Active
- 2012-06-29 BR BR112013033671-4A patent/BR112013033671B1/pt active IP Right Grant
- 2012-06-29 MX MX2018009524A patent/MX421100B/es unknown
- 2012-06-29 WO PCT/US2012/044988 patent/WO2013006454A1/en not_active Ceased
- 2012-06-29 KR KR1020147001595A patent/KR102061355B1/ko active Active
- 2012-06-29 MX MX2014000093A patent/MX358137B/es active IP Right Grant
-
2014
- 2014-01-21 ZA ZA2014/00490A patent/ZA201400490B/en unknown
-
2017
- 2017-05-18 JP JP2017098806A patent/JP2017186349A/ja active Pending
- 2017-11-21 AU AU2017265026A patent/AU2017265026B2/en active Active
-
2021
- 2021-03-30 US US17/216,769 patent/US11834491B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2726090B1 (en) | 2020-01-01 |
| KR102061355B1 (ko) | 2019-12-31 |
| CN103930124B (zh) | 2021-05-11 |
| US11834491B2 (en) | 2023-12-05 |
| JP2014518276A (ja) | 2014-07-28 |
| BR112013033671B1 (pt) | 2022-10-18 |
| JP2017186349A (ja) | 2017-10-12 |
| NZ620160A (en) | 2016-07-29 |
| AU2017265026A1 (en) | 2017-12-07 |
| US10995130B2 (en) | 2021-05-04 |
| WO2013006454A1 (en) | 2013-01-10 |
| ZA201400490B (en) | 2017-09-27 |
| AU2012279205B2 (en) | 2017-08-31 |
| MX2018009524A (es) | 2021-11-16 |
| MX421100B (es) | 2025-02-10 |
| DK2726090T3 (da) | 2020-01-20 |
| CN103930124A (zh) | 2014-07-16 |
| EA201490195A1 (ru) | 2014-04-30 |
| EA026226B1 (ru) | 2017-03-31 |
| MX2014000093A (es) | 2014-11-12 |
| AU2017265026B2 (en) | 2019-10-24 |
| US20210309719A1 (en) | 2021-10-07 |
| JP6463968B2 (ja) | 2019-02-06 |
| EP2726090A1 (en) | 2014-05-07 |
| KR20140056218A (ko) | 2014-05-09 |
| CA2840711C (en) | 2023-10-17 |
| AU2012279205A1 (en) | 2014-02-06 |
| CA2840711A1 (en) | 2013-01-10 |
| US20140255400A1 (en) | 2014-09-11 |
| CN113244374A (zh) | 2021-08-13 |
| BR112013033671A2 (pt) | 2017-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX358137B (es) | Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso. | |
| MX2023008559A (es) | Proteínas de fusión fc heterodiméricas il15/il15ra. | |
| PH12020550205A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
| PH12016502482A1 (en) | Process for the purification of tnfr:fc fusion protein | |
| MX389789B (es) | Moléculas del receptor de envolvimiento quimérico. | |
| EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
| WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
| NZ761188A (en) | Antibody molecules to tim-3 and uses thereof | |
| EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
| MX2015012553A (es) | Variantes de fc. | |
| MX377712B (es) | Anticuerpos dirigidos contra il-33 y sus usos. | |
| EA202091342A3 (ru) | Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения | |
| MX2016010953A (es) | Proteinas de fc multimericas. | |
| MX380520B (es) | Anticuerpos receptores de antitransferina y métodos de uso. | |
| EA202090031A3 (ru) | Человеческие антитела против gfr3 и способы их применения | |
| IN2014DN08721A (cg-RX-API-DMAC7.html) | ||
| EA201690992A1 (ru) | Антитела, специфичные к fcrn | |
| UA113879C2 (xx) | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ | |
| BR112015009462A2 (pt) | composição farmacêutica estável do tnfr:fc proteína de fusão | |
| MX371412B (es) | ANTICUERPOS BIESPECÍFICOS QUE SE UNEN ESPECÍFICAMENTE A LOXL2 Y ccl.2, COMPOSICIONES DE LOS MISMOS, Y SU USO EN EL TRATAMIENTO DE ESCLERODERMIA. | |
| MX338994B (es) | Composiciones de poliolefinas autoemulsionantes. | |
| LV15035A (lv) | Rekombinēta himēriska polipeptīda, kas satur melanokortīna otrā tipa receptoru (MC2R) un melanokortīnu receptoru palīgproteīnu (MRAP), kDNS secības, un tās izmantošana aktīvo vielu testēšanai un terapeitiskiem mērķiem | |
| EA201792475A1 (ru) | Клетки-предшественники мезодермальной линии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |